Previous Close | 40.37 |
Open | 40.13 |
Bid | 40.17 x 800 |
Ask | 41.00 x 1000 |
Day's Range | 39.96 - 40.70 |
52 Week Range | 31.01 - 50.21 |
Volume | |
Avg. Volume | 3,632,932 |
Market Cap | 20.547B |
Beta (5Y Monthly) | 0.63 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.16 (2.87%) |
Ex-Dividend Date | Feb 29, 2024 |
1y Target Est | N/A |
Besides Wall Street's top -and-bottom-line estimates for Baxter (BAX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures and a more stable supply chain.
ResMed (RMD) delivered earnings and revenue surprises of 10.94% and 1.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?